Sugi Predict

Sugi Predict / Compounds / SCHEMBL588912

SCHEMBL588912

SCHEMBL588912

COCC(NC(=O)OC(C)(C)C)C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ PPARA Q07869 6/20 0.53
▸ CTSS P25774 10/20 0.53
▸ CTSK P43235 8/20 0.53
▸ PPARG P37231 5/20 0.51
▸ CTSL P07711 2/20 0.50
▸ CTSB P07858 2/20 0.50
▸ ITGB3 P05106 1/20 0.46
▸ ITGA2B P08514 1/20 0.46
▸ ACE P12821 1/20 0.46
▸ PPARD Q03181 2/20 0.45
▸ CA1 P00915 1/20 0.45
▸ CA2 P00918 1/20 0.45
▸ CA7 P43166 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL580779 1.00 PPARA (0.53) PPARACTSSCTSKPPARGCTSL
SCHEMBL527131 1.00 PPARA (0.53) PPARACTSSCTSKPPARGCTSL
SCHEMBL8130419 0.95 PPARA (0.50) PPARACTSSCTSKPPARGCTSL
SCHEMBL30448077 0.88 PPARA (0.50) PPARACTSSCTSKPPARGCTSL
SCHEMBL1278066 0.88 PPARA (0.53) PPARACTSSCTSKPPARGCTSL
SCHEMBL27398769 0.87 PPARA (0.55) PPARACTSSCTSKPPARGCTSL
SCHEMBL27398770 0.87 PPARA (0.55) PPARACTSSCTSKPPARGCTSL
SCHEMBL25262348 0.86 CTSK (0.48) PPARACTSSCTSKPPARGCTSL
SCHEMBL953455 0.86 CTSK (0.48) PPARACTSSCTSKPPARGCTSL
SCHEMBL953453 0.86 CTSK (0.48) PPARACTSSCTSKPPARGCTSL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 277 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112521311-A Improved lacosamide intermediate preparation method 北京万全德众医药生物技术有限公司 2021-03-19 — — CN claimed
US-20130041180-A1 PROCESS FOR PREPARING (R)-2-ACETAMIDO-N-BENZYL-3-METHOXY-PROPIONAMIDE MSN LABORATORIES PRIVATE LIMITED (IN) 2013-02-14 — — US claimed
EP-2534127-A1 PROCESS FOR PREPARING (R)-2-ACETAMIDO-N-BENZYL-3-METHOXY-PROPIONAMIDE MSN Laboratories Limited (IN) 2012-12-19 — — EP claimed
CN-101928230-B Improved synthesis scheme for lacosamide UCB PHARMA GMBH 2012-11-07 — — CN claimed
WO-2011099033-A1 PROCESS FOR PREPARING (R)-2-ACETAMIDO-N-BENZYL-3-METHOXY-PROPIONAMIDE MSN LABORATORIES LIMITED (IN) 2011-08-18 — — WO claimed
CN-1989102-B Improved lacosamide synthesis method UCB PHARMA GMBH 2011-04-20 — — CN claimed
CN-101928230-A The synthetic method of improved scheme for lacosamide UCB PHARMA SA 2010-12-29 — — CN claimed
US-20260015313-A1 AMINO ACID ACTIVE ESTER AND SALT THEREOF PEPTIDREAM INC (JP) 2026-01-15 — — US disclosed
US-12485109-B2 Pyrrolo 12.3-dipyrimidine compounds and analogues thereof BIOCRYST PHARMACEUTICALS, INC. (US) 2025-12-02 — — US disclosed
US-12486262-B2 Compounds and uses thereof FOGHORN THERAPEUTICS INC. (US) 2025-12-02 — — US disclosed
US-20250320234-A1 LONP1 INHIBITOR COMPOUNDS, USES AND METHODS PRETZEL THERAPEUTICS, INC. (US) 2025-10-16 — — US disclosed
US-12383555-B2 Methods of treating cancers FOGHORN THERAPEUTICS INC. (US) 2025-08-12 — — US disclosed
EP-4143195-B1 IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 JANSSEN PHARMACEUTICA NV (BE) 2025-05-21 — — EP disclosed
US-20060084643-A1 Piperazine substituted aryl benzodiazepines ELI LILLY AND COMPANY 2006-04-20 — — US disclosed
WO-2006037574-A1 IMPROVED SYNTHESIS SCHEME FOR LACOSAMIDE SCHWARZ PHARMA AG (DE) 2006-04-13 — — WO disclosed
EP-1546134-A1 PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES ELI LILLY AND COMPANY (US) 2005-06-29 — — EP disclosed
EP-1525193-A2 ACYLAMINOTHIAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF Sanofi-Aventis (FR) 2005-04-27 — — EP disclosed
US-20050010031-A1 Melanocortin receptor ligands THE PROCTER & GAMBLE COMPANY 2005-01-13 — — US disclosed
WO-2004014895-A1 PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES ELI LILLY AND COMPANY (US) 2004-02-19 — — WO disclosed
WO-2004009565-A2 ACYLAMINOTHIAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2004-01-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050010031-A1 Melanocortin receptor ligands MC3R, MC5R, MC1R PPARA 2039/4885CTSS 4607/4885CTSK 4675/4885
US-20250320234-A1 LONP1 INHIBITOR COMPOUNDS, USES AND METHODS LONP1, NLN, ACAT1 PPARA 2100/4885CTSS 871/4885CTSK 1164/4885
US-12485109-B2 Pyrrolo 12.3-dipyrimidine compounds and analogues thereof C5, DPYD, C9 PPARA 2927/4885CTSS 1929/4885CTSK 2864/4885
US-20260015313-A1 AMINO ACID ACTIVE ESTER AND SALT THEREOF NSUN3, BCAT1, SLC43A1 PPARA 2794/4885CTSS 4022/4885CTSK 4661/4885
US-12486262-B2 Compounds and uses thereof VHL, CLN6, TFEB PPARA 1483/4885CTSS 2010/4885CTSK 2434/4885
US-20130041180-A1 PROCESS FOR PREPARING (R)-2-ACETAMIDO-N-BENZYL-3-METHOXY-PROPIONAMIDE AMY1A, PTMA, NAAA PPARA 3037/4885CTSS 2565/4885CTSK 3441/4885
US-20060084643-A1 Piperazine substituted aryl benzodiazepines GABBR1, GABBR2, GABRA5 PPARA 405/4885CTSS 4323/4885CTSK 4128/4885
US-12383555-B2 Methods of treating cancers MCL1, BRPF3, VHL PPARA 862/4885CTSS 784/4885CTSK 584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.